Trestle Biotherapeutics

Trestle Biotherapeutics

Biotechnology

Bioengineered Therapies for Kidney Disease

About us

Trestle Biotherapeutics, Inc. is a preclinical stage company developing bioengineered therapies for patients living with end stage renal disease. Once implanted, these bioengineered stem cell-derived tissues will get patients off dialysis, delay their need for transplantation, and one day become replacement organs.

Industry
Biotechnology
Company size
2-10 employees
Type
Privately Held

Employees at Trestle Biotherapeutics

Updates

Similar pages

Funding